Biotech, Developing & Developed Countries Vaccine Manufacturers COVID-19 Press Briefing - 23 Apr 21

On 23 April 2021, the Biotechnology Innovation Organization (BIO), Developing Countries Vaccine Manufacturers Network (DCVMN) and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) have organized a press briefing. They are all COVID-19 vaccine manufacturers partners of COVAX. The press briefing, hosted by IFPMA, will take stock of the contribution and difficulties of scaling up COVID-19 vaccines production, and the short and longer term challenges that need to be addressed to achieve equitable access to vaccines against COVID-19 pandemic.

Speakers included:

• BIO: Dr. Michelle McMurry-Heath, President & CEO, Biotechnology Innovation Organization (BIO)
• DCVMN: Rajinder, Rajinder Kumar Suri, Chief Executive Officer, Developing Countries Vaccine Manufacturers’ Network (DCVMN)
• GlaxoSmithKline: Roger Connor, President, Global Vaccines, GlaxoSmithKline & Vaccines CEO representative on COVAX
• Bharat Biotech International: Sai Prasad, Executive Director, Quality Operations, Bharat Biotech, President, Developing Countries Vaccine Manufacturers’ Network (DCVMN)
• Moderna: Stéphane Bancel, Chief Executive Officer, Moderna
• IFPMA: Thomas Cueni, Director General, International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)

Resources:
• Private sector statements at WTO event “COVID-19 and Vaccine Equity: What can the WTO Contribute”, Thomas Cueni, DG IFPMA Statement (15 April 2021): https://www.ifpma.org/resource-centre...
• COVAX, IFPMA, DCVMN press release (9 March 2021): “Meeting discusses COVID-19 vaccine manufacturing bottlenecks that must be urgently tackled for C19 vaccine output to reach its full potential”: https://www.ifpma.org/resource-centre...
• Virtual Press Briefing (recording) following the Global COVID-19 Vaccine Supply Chain & Manufacturing Summit 9 March 2021): https://www.ifpma.org/resource-centre...
• Towards Vaccinating the World Landscape of Current COVID-19 Supply Chain and Manufacturing Capacity, Potential Challenges, Initial Responses, and Possible “Solution Space” (9 March 2021): https://www.ifpma.org/wp-content/uplo...
• IFPMA COVID-19 Information Hub, with examples of how the biopharmaceutical industry is leading the way in developing vaccines, treatments and diagnostics: https://www.ifpma.org/covid19/

More about IFPMA:
IFPMA represents the research-based pharmaceutical companies and associations across the globe. The research-based pharmaceutical industry’s 2 million employees discover, develop, and deliver medicines and vaccines that improve the life of patients worldwide. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community find solutions that improve global health.

Visit our website: www.ifpma.org
Follow us on Twitter: @IFPMA
Follow us on LinkedIn: /ifpma